亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

北京弘潤(rùn)天源生物技術(shù) Cellonis Biotechnologies 
京弘潤(rùn)天源生物技術(shù)有限公司是一家專(zhuān)業(yè)從事細(xì)胞治療研究與臨床應(yīng)用的生物技術(shù)公司，公司秉承為細(xì)胞治療進(jìn)行最好推廣、最佳服務(wù)的宗旨，以“細(xì)胞治療的供應(yīng)和臨床服務(wù)”為運(yùn)營(yíng)理念，以搭建生產(chǎn)中心為核心的生產(chǎn)網(wǎng)絡(luò)是運(yùn)營(yíng)模式，以技術(shù)支持、細(xì)胞供應(yīng)、臨床研究和咨詢?yōu)榉?wù)方式，實(shí)現(xiàn)產(chǎn)業(yè)化發(fā)展。公司擁有通過(guò)SFDA認(rèn)證的GMP生產(chǎn)車(chē)間并配置先進(jìn)的細(xì)胞生產(chǎn)設(shè)備，擁有系統(tǒng)的細(xì)胞生產(chǎn)管理規(guī)范與管理制度，為細(xì)胞的臨床應(yīng)用提供了有效的保障。

Cellonis Biotechnologies Group is a China based biotechnology company focus primarily on the development and applying of novel stem cell technologies for providing the effective, patient-specific therapies to patients with degenerative central nervous system (CNS) disorders, cardiovascular diseases, liver diseases and cancers.

Based on the over 5 years experience of extensive research and treatment protocol development, we have built up an advance stem cell platform technology and more than 5 stem cell therapy programs have been used by partner hospitals for clinical research and treatment.

We have gotten the promising results from the clinical trails with our lead autologous adult stem cell and neural stem cell therapy programs for different kinds of CNS disorders such as parkinson's disease, post stroke, cerebral palsy, ALS (motor neuron disease), MS (multiple sclerosis), brain injury and spinal cord injury (SCI). And more than 100 patients experienced the stem cell therapy with our therapy programs. In addition to our CNS disorder programs, we are developing stem cell approaches for other conditions, including the liver diseases（hepatitis and cirrhosis.）, heart failure and peripheral artery diseases.

Cellonis is also advancing the cancer vaccine and cellular therapy for cancer. Our cancer vaccine programs which target at different kinds of solid tumor cells have showed great potential in cancer treatment. Currently Cellonis is exploring the novel cell therapies with the integration of its core stem cell technologies and immune technologies. The patented technologies will allow Cellonis to develop more effective cellular approaches for cancer relapse and metastasis.

Our headquarters and main facilities are located in Beijing. SinoTopCell Limited is a wholly-owned subsidiary of Cellonis located in Hong Kong focus on the international technology development and collaboration